Alan Swaisland

2.3k total citations · 1 hit paper
16 papers, 1.8k citations indexed

About

Alan Swaisland is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Alan Swaisland has authored 16 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Alan Swaisland's work include Lung Cancer Treatments and Mutations (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Alan Swaisland is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Alan Swaisland collaborates with scholars based in United Kingdom, United States and Brazil. Alan Swaisland's co-authors include Peter Sims, Alan Hewer, K. Pal, P.L. Grover, Georgina Speake, Carla M.L. van Herpen, Fred R. Hirsch, Serban Ghiorghiu, Philip L. Grover and Chonlakiet Khorprasert and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Alan Swaisland

16 papers receiving 1.7k citations

Hit Papers

Metabolic activation of b... 1974 2026 1991 2008 1974 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide
    1974 951 citations Peter Sims, P.L. Grover et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Swaisland United Kingdom 12 815 573 541 327 290 16 1.8k
Gi‐Ming Lai Taiwan 28 1.3k 1.6× 493 0.9× 828 1.5× 213 0.7× 103 0.4× 57 2.5k
Thomas L. Dao United States 34 725 0.9× 788 1.4× 1.0k 1.9× 308 0.9× 139 0.5× 124 3.0k
Chendil Damodaran United States 34 1.7k 2.1× 520 0.9× 680 1.3× 318 1.0× 91 0.3× 88 3.4k
K. Sree Kumar United States 30 673 0.8× 244 0.4× 211 0.4× 293 0.9× 80 0.3× 58 2.1k
Hongbiao Huang China 37 2.3k 2.9× 579 1.0× 833 1.5× 340 1.0× 50 0.2× 101 3.5k
Ying Sun China 24 1.1k 1.3× 392 0.7× 379 0.7× 207 0.6× 91 0.3× 93 2.1k
Janis Fleming United Kingdom 22 768 0.9× 276 0.5× 205 0.4× 197 0.6× 30 0.1× 31 1.4k
Robert F. Struck United States 25 686 0.8× 350 0.6× 392 0.7× 88 0.3× 377 1.3× 100 2.0k
Norman E. Sládek United States 32 1.9k 2.3× 811 1.4× 876 1.6× 119 0.4× 935 3.2× 80 3.7k
William J. Bodell United States 33 1.7k 2.1× 934 1.6× 397 0.7× 86 0.3× 186 0.6× 99 2.6k

Countries citing papers authored by Alan Swaisland

Since Specialization
Citations

This map shows the geographic impact of Alan Swaisland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Swaisland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Swaisland more than expected).

Fields of papers citing papers by Alan Swaisland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Swaisland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Swaisland. The network helps show where Alan Swaisland may publish in the future.

Co-authorship network of co-authors of Alan Swaisland

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Swaisland. A scholar is included among the top collaborators of Alan Swaisland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Swaisland. Alan Swaisland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Horák, Jiří, Jeff White, Adrian L. Harris, et al.. (2011). The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology. 68(6). 1485–1495. 25 indexed citations
2.
Gross, Mitchell E., Lawrence Leichman, Elizabeth Lowe, Alan Swaisland, & David B. Agus. (2011). Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology. 69(1). 273–280. 11 indexed citations
3.
Baselga, José, Andrés Cervantes, Erika Martinelli, et al.. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research. 16(19). 4876–4883. 95 indexed citations
4.
Dalton, R. Neil, et al.. (2010). Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.. PubMed. 30(7). 2935–42. 4 indexed citations
5.
Rukazenkov, Yuri, Georgina Speake, Gayle Marshall, et al.. (2009). Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anti-Cancer Drugs. 20(10). 856–866. 43 indexed citations
6.
Hannon, R.A., Glen Clack, Alan Swaisland, et al.. (2009). Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. Journal of Bone and Mineral Research. 25(3). 463–471. 89 indexed citations
7.
Stewart, J.S.W., Ezra E.W. Cohen, Lisa Licitra, et al.. (2009). Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology. 27(11). 1864–1871. 267 indexed citations
8.
Chhun, Stéphanie, Céline Verstuyft, Guy G. Simoneau, et al.. (2009). Gefitinib–phenytoin interaction is not correlated with the14C‐erythromycin breath test in healthy male volunteers. British Journal of Clinical Pharmacology. 68(2). 226–237. 32 indexed citations
9.
Trarbach, Tanja, Joachim Drevs, Dirk Strumberg, et al.. (2008). A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3592–3592. 6 indexed citations
10.
Chau, Ian, David Cunningham, Tamas Hickish, et al.. (2007). Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study. Annals of Oncology. 18(4). 730–737. 31 indexed citations
11.
Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, et al.. (2006). Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. Clinical Cancer Research. 12(3). 860–868. 155 indexed citations
12.
Millson, David, et al.. (1992). The effects of a selective 5‐HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.. British Journal of Clinical Pharmacology. 33(3). 281–288. 13 indexed citations
13.
14.
Sims, Peter, P.L. Grover, Alan Swaisland, K. Pal, & Alan Hewer. (1974). Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature. 252(5481). 326–328. 951 indexed citations breakdown →
15.
Swaisland, Alan, Philip L. Grover, & Peter Sims. (1974). Reactions of polycyclic hydrocarbon epoxides with RNA and polyribonucleotides. Chemico-Biological Interactions. 9(5). 317–326. 10 indexed citations
16.
Swaisland, Alan, Philip L. Grover, & Peter Sims. (1973). Some properties of “K-region” epoxides of polycyclic aromatic hydrocarbons. Biochemical Pharmacology. 22(13). 1547–1556. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gi‐Ming Lai Breakdown of academic impact, for papers by Thomas L. Dao Breakdown of academic impact, for papers by Chendil Damodaran Breakdown of academic impact, for papers by K. Sree Kumar Breakdown of academic impact, for papers by Hongbiao Huang Breakdown of academic impact, for papers by Ying Sun Breakdown of academic impact, for papers by Janis Fleming Breakdown of academic impact, for papers by Robert F. Struck Breakdown of academic impact, for papers by Norman E. Sládek Breakdown of academic impact, for papers by William J. Bodell
Rankless by CCL
2026